DermTech

DermTech Develops and Commercializes qPCR Testing Methods for Non-Invasive Skin Samples Collected Using a Tape Biopsy Method. The Company’s Tests Can Analyze Multiple Gene Targets to Evaluate Their RNA Expression Levels. DermTech Aims to Offer These Tests Through Its CLIA-Certified Laboratory Located in San Diego. Initially, the Company Will Provide a Test for Pigmented Skin Lesions Sampled Using the Tape Collection Method. DermTech Has Identified Differentially Expressed Gene Targets in Melanoma Samples (British Journal of Dermatology, April 2011). This Assay Can Assess RNA Expression Consistent with Melanoma with High Sensitivity (>95%) and Specificity (>70%).